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Background: Trisomy 12 (Tri12) chronic lymphocytic leukemia (CLL) iden-
tifies a cytogenetic subset with a peculiar clinical behavior (Bulian et al,
Haematologica, 2017) and specific biological features, including high fre-
quency of stabilizing NOTCH1 mutations (NOTCH1-mut) (Rossi et al,
Blood, 2013). Moreover, KRAS and its transcriptional regulator HNRNPA1,
key components of Ras-Raf-MEK-ERK pathway are both hosted in the tri-
somic chromosome 12.
Aims: To investigate the role of KRAS expression and/or activation in Tri12
and NOTCH1-mut CLL.
Methods: Tri12 was assessed by FISH. NOTCH1 and KRAS mutations
were assessed by either Sanger or NGS. QRT-PCR and western blot were
employed to evaluate HNRNPA1 and KRAS expression and down-stream
signaling in primary CLL or CLL cell line models. Active GTP-bound RAS
pull-down was performed by Raf1 RBD agarose beads assay. CI and MEC-
1 cell lines were used as human in vitro model of Tri12 NOTCH1-mut CLL
and non-Tri12 NOTCH1-wild type (wt) CLL, respectively. Mann-Whitney
test, unpaired t-test or Chi-Square test were used to compare differences
between groups.
Figure 1.
Results: KRAS transcript was analyzed in 215 cases purposely enriched in
Tri12 (118) and  NOTCH1-mut (121). As shown in Figure 1 A, Tri12 were
characterized by higher KRAS level in the context of NOTCH1-wt  CLL
(p=0.04); conversely, no differences in KRAS expression were found between
Tri12 and non-Tri12 in the context of NOTCH1-mut CLL cases, which
however expressed higher KRAS transcript compared to NOTCH1-wt CLL
(p=0.008). Consistently, KRAS protein level was higher in Tri12 vs. non-
Tri12 in the context of NOTCH1-wt CLL (Figure 1 B). A gene expression
profiling identified HNRNPA1 as the top ranked gene among MYC target
genes upregulated in NOTCH1-mut vs. NOTCH1-wt CLL. Accordingly,
higher HNRNPA1 levels were found by QRT-PCR in additional 41
NOTCH1-mut vs. 47 NOTCH1-wt CLL samples (p=0.003, Figure 1 C,D)
without differences between Tri12 (42) and non-Tri12 (46) CLL. In line
with a KRAS transcriptional activation mediated by NOTCH1-MYC-
HNRNPA1 axis, higher MYC, HNRNPA1 and KRAS protein levels were
found in the Tri12 NOTCH1-mut CI cell line when compared to the non-
Tri12 NOTCH1-wtMEC-1 cells. Furthermore, higher levels of active GTP-
bound KRAS and higher phosphorylation levels of MEK and ERK were
found in CI cells (Figure 1 E,F,G), supporting the hypothesis of sustained
Ras-Raf-MEK-ERK signaling in Tri12 and NOTCH1-mut CLL. Finally,
analysis of KRAS genomic aberrations revealed higher mutations incidence
in Tri12 CLL (10/77, 13%) when compared to non-Tri12 CLL (2/68, 2.9%,
p=0.03). Altogether, these data foster the hypothesis of multiple mechanisms
of KRAS overexpression/activation occurring in Tri12 CLL via the
NOTCH1-MYC-HNRNPA1 axis in NOTCH1-mut cases, or due to a high-
er incidence of KRAS mutations or an overexpression of KRAS by the super-
numerary chromosome 12 (Figure 1 H).
Summary/Conclusion: Our data, by describing a synergism between Tri12,
NOTCH1-mut and KRAS-mut in boosting KRAS expression and activity
in CLL, indicate the Tri12 subset as particularly addicted to the Ras-Raf-
MEK-ERK signaling pathway and likely to benefit of ERK/MEK inhibitors,
as recently emphasized (Dietrich et al, J Clin Invest, 2018).
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Background: Treatment of high-risk chronic lymphocytic leukemia (CLL)
patients remains an unmet clinical need. Disease aggressiveness can be
ascribed to intrinsic features of the tumor cells (i.e. TP53 disruption) and to
the interaction of CLL cells with stromal cells (SC) of the microenvironment.
HIF-1 is a transcription factor implicated in cell adaptation to hypoxia and
is involved in the regulation of genes implicated in tumor progression. In
CLL cells, the α subunit of HIF-1 (HIF-1α) is constitutively expressed even
in normoxia and regulates the protective interactions that the leukemic cells
establish with the microenvironment.
Aims: The aims of this study were to understand HIF-1α regulatory path-
ways in CLL cells from TP53 disrupted (TP53dis) and wild type (TP53wt)
patients, and to evaluate the ability of HIF-1α inhibition to exert synergistic
cytotoxic effects in combination with fludarabine and ibrutinib.
Methods: Del(17p) in CLL cells was assessed by fluorescence in situ
hybridization and the presence of TP53 gene mutations was evaluated by
Sanger sequencing. CLL patients with mutation of the TP53 gene, or >40%
del(17p) in the absence of TP53 mutation, were included in the TP53dis sub-
set. Patients with <10% del(17p) and without TP53 mutation were consid-
ered TP53wt. In selected experiments, CLL cells were cultured in the presence
or absence of M2-10B4 SC, and exposed to PD98059, Y27632, LY249002,
BAY87-2243, F-ara-A or ibrutinib. Culture conditions were 21% (normox-
ia) or 1% (hypoxia) O2, 5% CO2 at 37°C. Ras, ERK1-2, Akt, HIF-1α,
Elk3 and pVHL expression was evaluated by Western Blot. RhoA and RhoA
kinase acitivity was measured by specific immunoassays. HIF-1A, p21 and
ENO1 gene expression was assessed by RT-PCR. Cell viability was analyzed
by AnnexinV/propidium Iodide immunostaining.
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Results: We found that primary CLL cells from patients carrying TP53
abnormalities (TP53dis CLL cells) had constitutively higher transcriptional
activity and expression levels of the α subunit of HIF-1 compared to CLL
cells isolated from TP53wt samples (TP53wt CLL cells). HIF-1α upregulation
detected in the TP53dissubset was due to a reduced expression of the HIF-
1α ubiquitin ligase von Hippel-Lindau protein (pVHL) and more active
PI3K/Akt and Ras/ERK1-2 signalling pathways. Hypoxia and SC further
enhanced HIF-1α accumulation in both TP53dis and TP53wt CLL cells.
Hypoxia-mediated HIF-1α upregulation was due to a decreased pVHL
expression and to the activation of PI3K/Akt and Ras/ERK1-2 signalling
pathways. SC did not affect pVHL expression, but induced an increased
activity of Ras/ERK1-2, RhoA/RhoA kinase and PI3K/Akt pathways, lead-
ing to HIF-1α accumulation. Interestingly, in vitro fludarabine-resistant
CLL cells were mostly TP53dis and expressed significantly higher levels of
HIF-1A mRNA compared to fludarabine-sensitive cells. The HIF-1α
inhibitor BAY87-2243 reversed the constitutive fludarabine resistance of
leukemic cells isolated from patients carrying TP53 abnormalities, and coun-
teracted the fludarabine resistance induced by SC. BAY87-2243 also elicited
a strongly synergistic cytotoxic effect in combination with ibrutinib.
Summary/Conclusion: Overall, our data indicate that HIF-1α is overex-
pressed in CLL cells, especially in the presence of TP53 abnormalities, and
is susceptible of positive regulation by hypoxia and SC. From the transla-
tional standpoint, HIF-1α can be regarded as a crucial target whose inhibi-
tion warrants further evaluation, also in combination with currently avail-
able therapies.
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Background: The B-cell receptor (BCR) is one of the most important surface
molecules that CLL cells use to gain oncogenic signals from the microenvi-
ronment. The critical role of BCR signaling for the pathogenesis of CLL is
supported by the therapeutic success of ibrutinib, a targeted agent that dis-
rupts the BCR pathway. Beside microenvironment-promoted oncogenic sig-
nals, the biology of CLL is also driven by molecular lesions and clonal evo-
lution, that mark CLL progression and treatment resistance. The intercon-
nection between microenvironment-promoted oncogenic signals and clonal
evolution has been postulated in CLL but never proven because of the lack
of suitable ex vivo models. 
Aims: Ibrutinib allows the unprecedented opportunity of assessing the con-
tribution of BCR to cancer clonal evolution directly in vivo in patients.
Methods: The IOSI-EMA-001 study (NCT02827617) is an observational,
non-interventional, multicenter study consisting in the prospective and lon-
gitudinal collection of peripheral blood samples and clinical data from high
risk CLL patients treated with ibrutinib monotherapy. Tumor DNA derived
from sorted CLL cells (purity >99%) and germline DNA derived from sorted
T cells were used for somatic mutation identification by CAPP-seq targeted
deep next generation. A gene panel including 133 genes recurrently mutated
in mature B-cell tumors or targeted by the aberrant somatic hypermutation
process, was used. The number of the libraries loaded in the NexSeq500
sequencer (Illumina) was tailored at obtaining at least a coverage >2000x
in >80% of the region of interest. A stringent bioinformatic pipeline was
applied to suppress the background noise allowing to call variants with a
sensitivity of 3x10–3. To track clonal trajectories across serial samples, we
first measured the variant allele fraction (VAF) of all mutations identified
across the different timepoints per patient. VAFs were transformed to cancer
cell fractions (CCFs) using the ABSOLUTE tool. For each patient, we com-
pared the clonal composition of the baseline sample with all the available
longitudinal samples (up to 72 weeks of therapy).
Results: The study cohort comprised 31 high risk CLL patients, including
15 treatment naïve, 16 relapsed, 80% IGHV unmutated, 42% 17p deleted
and 55% TP53 mutated (Figure 1A). Median duration of ibrutinib treat-
ment was 45 weeks (range 24-72 weeks). Overall, 285 individual mutations
were longitudinally discovered and monitored across a total of 119 sequen-
tial timepoints collected during ibrutinib treatment. Significant changes in
CCF over time, defined as a FDR adjusted p value of <0.1 for change in
CCF >0.1 in the largest rising or falling clone was observed in 21/31 (67.7%)
cases (Figure 1B), a proportion that is superimposable to the clonal evolution
rate previously documented in CLL treated with chemoimmunotherapy.
Clonal evolution appeared to be puzzled and involved different genes with-
out a stereotypic targeting (Figure 1C). Consistently, none of the main driver
gene mutations was homogeneously selected or suppressed by ibrutinib.
Clonal evolution rate neither associated with IGHV or TP53 mutation status
(Figure 1D), nor changed over time (Figure 1E).
Figure 1.
Summary/Conclusion: Our results suggest that clonal evolution, a known
pathogenic mechanism of progressive CLL: i) is not abrogated by ibrutinib;
and ii) is quantitatively similar, but qualitatively different, than clonal evo-
lution under chemoimmunotherapy, without specific pathways being tar-
geted.
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Background: The addition of the anti-CD20 monoclonal antibody (mAb)
rituximab to chemotherapy improves responses in almost all chronic lym-
phocytic leukaemia (CLL) patients, with the exception of those having
NOTCH1mutations. NOTCH1 is a cell surface receptor releasing its intra-
cellular domain (NICD1) after two ligand-induced cleavage steps per-
formed by metalloproteases and γ-secretase. NICD1 acts as transcription
factor and NOTCH1 mutations in CLL lead to longer lasting transcription
factor activity.
Aims: To understand the relationship between rituximab and NOTCH1,
we studied the effects rituximab treatment has on NOTCH1 signalling.
Methods: Freshly isolated peripheral blood mononuclear cells (PBMCs)
from CLL patients attending St. Bartholomew’s Hospital, London were
enriched for CD19+ cells and treated with rituximab. Whole protein lysates
were obtained after 15, 30 and 60 min of mAb treatment; RNA was isolated
after 150 min. NICD1 was semi-quantitatively assessed by western blot.
Expression of HES1, the best established NICD1 target gene, and CCL2
was quantified by TaqMan-probe-based quantitative PCR. Rituximab
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